A Randomised, Open-label, Parallel Controlled, Multicentre, Phase 3 Clinical Trial of Pyrotinib Plus Capecitabine Versus Lapatinib Plus Capecitabine in Patients With HER2+ Metastatic Breast Cancer:
Not yet recruiting
Phase of Trial: Phase III
Latest Information Update: 13 Apr 2017
At a glance
- Drugs Capecitabine (Primary) ; Pyrotinib (Primary) ; Lapatinib
- Indications Breast cancer
- Focus Therapeutic Use
- Sponsors Jiangsu Hengrui Medicine Co.
- 07 Apr 2017 Planned number of patients changed from 470 to 240.
- 17 Mar 2017 New trial record
- 16 Mar 2017 Planned number of patients changed from 240 to 470.